Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-06-2014 | Retinal Disorders

Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment

Authors: Sirpa Loukovaara, Kaisa Lehti, Alexandra Robciuc, Timo Pessi, Juha M. Holopainen, Katri Koli, Ilkka Immonen, Jorma Keski-Oja

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 6/2014

Abstract

Purpose

To explore factors related to pathogenesis of rhegmatogenous retinal detachment (RRD) and development of proliferative vitreoretinopathy (PVR), vitreous levels of angiopoietin-1 and −2 (Ang-1 and −2), previously undefined in RRD, transforming growth factor-(TGF) β1, vascular endothelial growth factor (VEGF), erythropoietin (EPO) and proteolytic mediators of extracellular matrix remodelling (MMP-2 and −9) were compared in eyes with RRD and eyes with idiopathic macular hole or pucker.

Methods

Vitreous samples were collected from 117 eyes with RRD (study group) and 40 eyes with macular hole or pucker (control group). Growth factors were measured by ELISA and matrix metalloproteinases (MMPs) by gelatin zymography.

Results

The mean vitreous concentrations of Ang-2, MMP-2, and MMP-9 were higher (all p < 0.01), whereas concentration of VEGF was lower (p = 0.01) in eyes with RRD relative to controls. Logistic regression analysis identified Ang-2 concentration as a novel marker of RRD (p = 0.0001, OR 48.7). Ang-1, EPO, and total TGF-β1 levels were not significantly different between the groups. However, TGF-β1 and MMP-2 were increased in eyes with total RRD compared to those with local RRD (p ≤ 0.05). In eyes with PVR, no differences were observed in any studied marker as compared with non-PVR eyes.

Conclusions

Current results reveal Ang-2 as a key factor upregulated in RRD. It may co-operate with fibrosis-associated factors and contribute to vascular complications such as breakdown of blood–eye barrier and PVR development.

Lewis GP, Guerin CJ, Anderson DH, Matsumoto B, Fisher SK (1994) Rapid changes in the expression of glial cell proteins caused by experimental retinal detachment. Am J Ophthalmol 118:368–376PubMed

Cook B, Lewis GP, Fisher SK, Adler R (1995) Apoptotic photoreceptor degeneration in experimental retinal detachment. Invest Ophthalmol Vis Sci 36:990–996PubMed

Mitry D, Fleck BW, Wright AF, Campbell H, Charteris DG (2010) Pathogenesis of rhegmatogenous retinal detachment — predisposing anatomy and cell biology. Retina 30:1561–1572PubMedCrossRef

Lo ACY, Woo TTY, Wong RLM, Wong D (2011) Apoptosis and other cell death mechanisms after retinal detachment: implications for photoreceptor rescue. Ophthalmologica 226(suppl 1):10–17PubMedCrossRef

Hui YH, Goodnight R, Zhang XJ, Sorgente N, Ryan SJ (1988) Glial epiretinal membranes and contraction. Immunohistochemical and morphological studies. Arch Ophthalmol 106:1280–1285PubMedCrossRef

Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, Yeo KT (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118:445–450PubMed

Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMedCrossRef

Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M (2002) Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Am J Ophthalmol 133:851–852PubMedCrossRef

Kvanta A (2006) Ocular angiogenesis: the role of growth factors. Review article. Acta Ophthalmol Scand 84:282–288PubMedCrossRef

10.

Rasier R, Gormus U, Artunay O, Yuzbasioglu E, Oncel M, Bahcecioglu H (2010) Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment. Curr Eye Res 35(6):505–509PubMedCrossRef

11.

Ricker LJAG, Diedonne SC, Kessels AG, Rennel ES, Berendschot TT, Hendrikse F, Kijlstra A, La Heij EC (2012) Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Retina 32(1):54–59PubMedCrossRef

12.

Fiedler U, Augustin HG (2006) Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27(12):552–558PubMedCrossRef

13.

Tsanou E, Ioachim E, Stefaniotou M, Gorezis S, Charalabopoulos K, Bagli H, Peschos D, Psilas K, Agnantis NJ (2005) Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes. Int J Clin Pract 59(10):1157–1161PubMedCrossRef

14.

Roberts A, Sporn MB (1993) Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 8:1–9PubMedCrossRef

15.

Sivak JM, Fini ME (2002) MMPs in the eye: emerging roles if or matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 21:1–14PubMedCrossRef

16.

Brown D, Hamdi H, Bahri S, Kennedy MC (1994) Characterization of an endogenous metalloproteinase in human vitreous. Curr Eye Res 13:639–647PubMedCrossRef

17.

Abu El-Asrar AM, Dralands L, Veckeneer M, Geboes K, Missotten L, Van Aelst I, Opdenakker G (1998) Gelatinase B in proliferative vitreoretinal disorders. Am J Ophthalmol 125:844–851PubMedCrossRef

18.

De La Paz MA, Itoh Y, Toth CA, Nagase H (1998) Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci 39:1256–1260

19.

Kosano H, Okano T, Katsura Y, Noritake M, Kado S, Matsuoka T, Nishigori H (1999) ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci 64:2307–2315PubMedCrossRef

20.

Das A, McGuire PG, Eriqat C, Ober RR, DeJuan E Jr, Williams GA, McLamore A, Biswas J, Johnson DW (1999) Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 40:809–813PubMed

21.

Salzmann J, Limb GA, Khaw PT, Gregor ZJ, Webster L, Chignell AH, Charteris DG (2000) Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 84:1091–1096PubMedCentralPubMedCrossRef

22.

Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M, Tsukahara S (2001) Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 21:28–33PubMedCrossRef

23.

Noda K, Ishida S, Inoue M, Obata K, Oguchi Y, Okada Y, Ikeda E (2003) Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 44(5):2163–2170PubMedCrossRef

24.

Beránek M, Kolar P, Tschoplova S, Kankova K, Vasku A (2008) Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol Vis 14(14):1114–1121PubMedCentralPubMed

25.

Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT (1998) A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 39(8):1524–1529PubMed

26.

Symeonidis C, Diza E, Papakonstantinou E, Souliou E, Dimitrakos SA, Karakiulakis G (2007) Correlation of the extent and duration of rhegmatogenous retinal detachment with the expression of matrix metalloproteinases in the vitreous. Retina 27(9):1279–1285PubMedCrossRef

27.

Symeonidis C, Papakonstantinou E, Souliou E, Karakiulakis G, Dimitrakos SA, Diza E (2011) Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta Ophthalmol Scand 89(4):339–345CrossRef

28.

Simo R, Carrasco E, Garcia-Remez M, Hernandez C (2006) Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diab Rev 2:71–98CrossRef

29.

Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A (1999) Deficient activation and different expression of transforming growth factor-beta isoforms in active proliferative diabetic retinopathy and neovascular eye disease. Exp Clin Endocrinol Diabetes 107:21–28PubMedCrossRef

30.

Kita T, Hata Y, Arita R, Kawahara S, Miura M, Nakao S, Mochizuki Y, Enaida H, Goto Y, Shimokawa H, Hafezi-Moghadam A, Ishibashi T (2008) Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci U S A 105(45):17504–17509PubMedCentralPubMedCrossRef

31.

Manzoni P, Maestri A, Gomirato G, Takagi H, Watanabe D, Matsui S (2005) Erythropoietin as a retinal angiogenic factor. N Engl J Med 353:2190–2191PubMedCrossRef

32.

Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H (2005) Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353:782–792PubMedCrossRef

33.

Caprara C, Grimm C (2012) From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. Prog Retin Eye Res 31:89–119PubMedCrossRef

34.

Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Ceramil A, Brines M, Rosenbaum DM (2002) Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. PNAS 16:10659–10664CrossRef

35.

Inomata Y, Hirata A, Takahashi E, Kawaji T, Fukushima M, Tanihara H (2004) Elevated erythropoietin in vitreous with ischemic retinal diseases. Neuroreport 15:877–879PubMedCrossRef

36.

Retina Society Terminology Committee (1991) An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 112:159–165

37.

Saharinen P, Alitalo K (2011) The yin, the yang, and the angiopoietin-1. J Clin Invest 121(6):2157–2159PubMedCentralPubMedCrossRef

38.

Lohi J, Lehti K, Westermarck J, Kahari VM, Keski-Oja J (1996) Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem 239(2):239–247PubMedCrossRef

39.

Lobov IB, Brooks PC, Lang RA (2002) Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99:11205–11210PubMedCentralPubMedCrossRef

40.

Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55–60PubMedCrossRef

41.

Nambu H, Nambu R, Oshima Y, Hackett SF, Okoye G, Wiegand S, Yancopoulos G, Zack DJ, Campochiaro PA (2004) Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther 11(19):865–873PubMedCrossRef

42.

Thurston G, Rudge J, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6:460–463PubMedCrossRef

43.

Kim I, Moon S-O, Park SK (2001) Angiopoietin-1 reduces VEGF-stimulated leucocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin Expression. Circ Res 89:477–479PubMedCrossRef

44.

Kwak HJ, So JN, Lee SJ, Kim I, Koh GY (1999) Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 448:249–253PubMedCrossRef

45.

Brindle NPJ, Saharinen P, Alitalo K (2006) Signaling and functions of angiopoietin-1 in vascular protection. Circ Res 98:1014–1023PubMedCentralPubMedCrossRef

46.

Ganter MT, Cohen MJ, Brohi K, Chesebro BB, Staudenmayer KL, Rahn P, Christiaans SC, Bir ND, Pittet JF (2008) Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma? Ann Surg 247(2):320–326PubMedCrossRef

47.

Sieczkiewicz GJ, Herman IM (2003) TGF-beta 1 signaling controls retinal pericyte cotractile protein expression. Microvasc Res 66:190–196PubMedCrossRef

48.

Hoerster R, Hermann MM, Rosentreter A, Muether PS, Kirchhof B, Fauser S (2013) Profibrotic cytokines in aqueous humor correlate with aqueous flare in patients with rhegmatogenous retinal detachment. Br J Ophthalmol 97:450–453PubMedCrossRef

49.

Pfeffer BA, Flanders KC, Guerin CJ (1994) Transforming growth factor beta2 is the predominant isoform in the neural retina, retinal pigment epithelium–choroid and vitreous of the monkey eye. Exp Eye Res 59:323–333PubMedCrossRef

50.

Gerhardinger C, Dagher Z, Sebastiani P, Park YS, Lorenzi M (2009) The transforming growth factor-[beta] pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 58(7):1659–1667PubMedCentralPubMedCrossRef

51.

Xie Z, Wu X, Qiu Q, Gong Y, Song Y, Gu Q, Li C (2007) Expression pattern of erythropoietin and erythropoietin receptor in experimental model of retinal detachment. Curr Eye Res 32:757–764PubMedCrossRef

52.

Wang ZY, Shen LJ, Zhao KK, Song ZM, Qu J (2009) Elevated erythropoietin in vitreous of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy. Ophthalmic Res 42(3):138–140PubMedCrossRef

53.

Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui T-G, Sugiono M, Waine E, Perrin R, Foster R, Digby-Bell J, Shields JD, Whittles CE, Mushens RE, Gillatt DA, Ziche M, Harper SJ, Bates DO (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64:7822–7835PubMedCrossRef

54.

Shitama T, Hayashi H, Noge S (2008) Proteome profiling of vitreoretinal diseases by cluster analysis. Proteomics Clin Appl 2(9):1265–1280PubMedCentralPubMedCrossRef

Title: Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment
Authors: Sirpa Loukovaara
Kaisa Lehti
Alexandra Robciuc
Timo Pessi
Juha M. Holopainen
Katri Koli
Ilkka Immonen
Jorma Keski-Oja
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 6/2014
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-013-2508-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2014

Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration

Pars plana vitrectomy for treatment of advanced Coats’ disease—presentation of a modified surgical technique and long-term follow-up

Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis

Partial lamellar keratoplasty for peripheral corneal disease using a graft from the glycerin-preserved corneoscleral rim

Investigating retinal toxicity of tempol in a model of isolated and perfused bovine retina

Erratum to: Foveola nonpeeling internal limiting membrane surgery to prevent inner retinal damages in early stage 2 idiopathic macula hole